Aghemo A, Bruno R, Colombo M, Medagli M, Puoti M, Rizzardini G, Fagiuoli S
Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.
Eur Rev Med Pharmacol Sci. 2016 Dec;20(1 Suppl):17-19.
The arrival of potent directly acting antivirals (DAAs) for the treatment of chronic Hepatitis C virus (HCV) infection was a challenge for the regional health system of the Lombardia Region. Lombardia represents roughly 8% of the Italian territory but includes nearly 16% of the Italian population. In 2014, nearly 37,600 HCV patients were routinely followed-up in liver centers across the region; nearly 16,000 were classified as having advanced fibrosis or cirrhosis (Metavir F3-F4). The creation of a regional network was necessary to ensure uniformity in treatment access and treatment management. The first database analysis of the Lombardia Hepatitis Network was conducted in January 2016, and included data on 2432 patients who had received treatment from December 2014 to December 2015. The most prevalent HCV genotypes were HCV-1 found in 63% and HCV-3 found in 17%. Overall 90.4% patients achieved an SVR, SVR rates were 92.9% in HCV-1, 89.3% in HCV-2, 81.1% in HCV-3 and 88.9% in HCV-4.
强效直接作用抗病毒药物（DAAs）用于治疗慢性丙型肝炎病毒（HCV）感染，这对伦巴第大区的区域卫生系统构成了一项挑战。伦巴第大区约占意大利领土的8%，但却容纳了近16%的意大利人口。2014年，该地区各肝病中心对近37600例HCV患者进行了常规随访；近16000例被归类为有严重纤维化或肝硬化（梅塔维分级F3 - F4）。建立一个区域网络对于确保治疗可及性和治疗管理的一致性是必要的。伦巴第肝炎网络的首次数据库分析于2016年1月进行，纳入了2014年12月至2015年12月期间接受治疗的2432例患者的数据。最常见的HCV基因型是HCV - 1型，占63%，HCV - 3型占17%。总体而言，90.4%的患者实现了持续病毒学应答（SVR），HCV - 1型的SVR率为92.9%，HCV - 2型为89.3%，HCV - 3型为8,1.1%，HCV - 4型为88.9%。
